One of the jewels of the UK biotech sector, BenevolentAI Limited, is to go public with a €1.5bn valuation in Amsterdam via the largest merger to date with a special purpose acquisition company (SPAC).
BenevolentAI Goes Public In Europe’s Largest SPAC
Valued at €1.5bn
The UK computational medicines specialist is listing on the Euronext Amsterdam after linking up with healthcare-focused special purpose acquisition corporation Odyssey which is advised by former Sanofi CEO Olivier Brandicourt.
